More recently, one report demonstrated the added benefit of combining both VEGFR and c-Met inhibitors in an NB in vivo orthotopic model on reduction of tumor growth, inhibition of neovascularization and metastasis, and enhanced apoptosis (Daudigeos-Dubus et al., 2017). Here, MET is linked to neoplasm.